26
|
Garland SN, Johnson JA, Carlson LE, Rodriguez N, Savard J, Campbell T. 0864 A Randomized Controlled Trial of Light Therapy for Insomnia Symptoms in Fatigued Cancer Survivors. Sleep 2018. [DOI: 10.1093/sleep/zsy061.863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Bassetti M, Lang J, Morris Z, Morris B, Eickhoff J, Traynor A, Campbell T, Matkowskyj K, Baschnagel A, Leal T. P3.04-009 Stereotactic Body Radiotherapy to All Sites of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Combined with Durvalumab and Tremelimumab. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1667] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
28
|
Sissung TM, Ley AM, Strope JD, McCrea EM, Beedie S, Peer CJ, Shukla S, van Velkinburgh J, Reece K, Troutman S, Campbell T, Fernandez E, Huang P, Smith J, Thakkar N, Venzon DJ, Brenner S, Lee W, Merino M, Luo J, Jager W, Price DK, Chau CH, Figg WD. Differential Expression of OATP1B3 Mediates Unconjugated Testosterone Influx. Mol Cancer Res 2017; 15:1096-1105. [PMID: 28389619 PMCID: PMC5540879 DOI: 10.1158/1541-7786.mcr-16-0477] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 02/06/2017] [Accepted: 04/04/2017] [Indexed: 12/21/2022]
Abstract
Castration-resistant prostate cancer (CRPC) has greater intratumoral testosterone concentrations than similar tumors from eugonadal men; simple diffusion does not account for this observation. This study was undertaken to ascertain the androgen uptake kinetics, functional, and clinical relevance of de novo expression of the steroid hormone transporter OATP1B3 (SLCO1B3). Experiments testing the cellular uptake of androgens suggest that testosterone is an excellent substrate of OATP1B3 (Km = 23.2 μmol/L; Vmax = 321.6 pmol/mg/minute), and cells expressing a doxycycline-inducible SLCO1B3 construct had greater uptake of a clinically relevant concentration of 3H-testosterone (50 nmol/L; 1.6-fold, P = 0.0027). When compared with Slco1b2 (-/-) mice, Slco1b2 (-/-)/hSLCO1B3 knockins had greater hepatic uptake (15% greater AUC, P = 0.0040) and lower plasma exposure to 3H-testosterone (17% lower AUC, P = 0.0030). Of 82 transporters genes, SLCO1B3 is the second-most differentially expressed transporter in CRPC cell lines (116-fold vs. androgen-sensitive cells), with a differentially spliced cancer-type ct-SLCO1B3 making up the majority of SLCO1B3 expression. Overexpression of SLCO1B3 in androgen-responsive cells results in 1.5- to 2-fold greater testosterone uptake, whereas siRNA knockdown of SLCO1B3 in CRPC cells did not change intracellular testosterone concentration. Primary human prostate tumors express SLCO1B3 to a greater extent than ct-SLCO1B3 (26% of total SLCO1B3 expression vs. 0.08%), suggesting that androgen uptake in these tumor cells also is greater. Non-liver tumors do not differentially express SLCO1B3.Implications: This study suggests that de novo OATP1B3 expression in prostate cancer drives greater androgen uptake and is consistent with previous observations that greater OATP1B3 activity results in the development of androgen deprivation therapy resistance and shorter overall survival. Mol Cancer Res; 15(8); 1096-105. ©2017 AACR.
Collapse
|
29
|
Senteio C, Hershey D, Campbell T. DIABETES EDUCATION AND INTERGENERATIONAL TECHNOLOGY TRANSFER. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.5155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Senteio C, Hershey D, Campbell T. DIABETES EDUCATION AND INTERGENERATIONAL TECHNOLOGY TRANSFER. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.4324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Abe K, Amey J, Andreopoulos C, Antonova M, Aoki S, Ariga A, Autiero D, Ban S, Barbi M, Barker GJ, Barr G, Barry C, Bartet-Friburg P, Batkiewicz M, Berardi V, Berkman S, Bhadra S, Bienstock S, Blondel A, Bolognesi S, Bordoni S, Boyd SB, Brailsford D, Bravar A, Bronner C, Buizza Avanzini M, Calland RG, Campbell T, Cao S, Cartwright SL, Catanesi MG, Cervera A, Checchia C, Cherdack D, Chikuma N, Christodoulou G, Clifton A, Coleman J, Collazuol G, Coplowe D, Cudd A, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Dewhurst D, Di Lodovico F, Di Luise S, Dolan S, Drapier O, Duffy KE, Dumarchez J, Dziewiecki M, Emery-Schrenk S, Ereditato A, Feusels T, Finch AJ, Fiorentini GA, Friend M, Fujii Y, Fukuda D, Fukuda Y, Galymov V, Garcia A, Giganti C, Gizzarelli F, Golan T, Gonin M, Hadley DR, Haegel L, Haigh MD, Hansen D, Harada J, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Helmer RL, Hillairet A, Hiraki T, Hiramoto A, Hirota S, Hogan M, Holeczek J, Hosomi F, Huang K, Ichikawa AK, Ikeda M, Imber J, Insler J, Intonti RA, Ishida T, Ishii T, Iwai E, Iwamoto K, Izmaylov A, Jamieson B, Jiang M, Johnson S, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Katori T, Kearns E, Khabibullin M, Khotjantsev A, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kondo K, Kormos LL, Korzenev A, Koshio Y, Kowalik K, Kropp W, Kudenko Y, Kurjata R, Kutter T, Lagoda J, Lamont I, Lamoureux M, Larkin E, Lasorak P, Laveder M, Lawe M, Licciardi M, Lindner T, Liptak ZJ, Litchfield RP, Li X, Longhin A, Lopez JP, Lou T, Ludovici L, Lu X, Magaletti L, Mahn K, Malek M, Manly S, Marino AD, Martin JF, Martins P, Martynenko S, Maruyama T, Matveev V, Mavrokoridis K, Ma WY, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Mijakowski P, Minamino A, Mineev O, Mine S, Missert A, Miura M, Moriyama S, Mueller TA, Myslik J, Nakadaira T, Nakahata M, Nakamura KG, Nakamura K, Nakamura KD, Nakanishi Y, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Nielsen C, Nirkko M, Nishikawa K, Nishimura Y, Novella P, Nowak J, O'Keeffe HM, Okumura K, Okusawa T, Oryszczak W, Oser SM, Ovsyannikova T, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Patel ND, Paudyal P, Pavin M, Payne D, Perkin JD, Petrov Y, Pickard L, Pickering L, Pinzon Guerra ES, Pistillo C, Popov B, Posiadala-Zezula M, Poutissou JM, Poutissou R, Przewlocki P, Quilain B, Radermacher T, Radicioni E, Ratoff PN, Ravonel M, Rayner MA, Redij A, Reinherz-Aronis E, Riccio C, Rodrigues PA, Rondio E, Rossi B, Roth S, Rubbia A, Rychter A, Sakashita K, Sánchez F, Scantamburlo E, Scholberg K, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaw D, Shiozawa M, Shirahige T, Short S, Smy M, Sobczyk JT, Sobel H, Sorel M, Southwell L, Steinmann J, Stewart T, Stowell P, Suda Y, Suvorov S, Suzuki A, Suzuki SY, Suzuki Y, Tacik R, Tada M, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Terhorst D, Terri R, Thakore T, Thompson LF, Tobayama S, Toki W, Tomura T, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Vagins M, Vallari Z, Vasseur G, Vladisavljevic T, Wachala T, Walter CW, Wark D, Wascko MO, Weber A, Wendell R, Wilkes RJ, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Wret C, Yamada Y, Yamamoto K, Yamamoto M, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Yoshida K, Yuan T, Yu M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Combined Analysis of Neutrino and Antineutrino Oscillations at T2K. PHYSICAL REVIEW LETTERS 2017; 118:151801. [PMID: 28452532 DOI: 10.1103/physrevlett.118.151801] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/03/2017] [Indexed: 06/07/2023]
Abstract
T2K reports its first results in the search for CP violation in neutrino oscillations using appearance and disappearance channels for neutrino- and antineutrino-mode beams. The data include all runs from January 2010 to May 2016 and comprise 7.482×10^{20} protons on target in neutrino mode, which yielded in the far detector 32 e-like and 135 μ-like events, and 7.471×10^{20} protons on target in antineutrino mode, which yielded 4 e-like and 66 μ-like events. Reactor measurements of sin^{2}2θ_{13} have been used as an additional constraint. The one-dimensional confidence interval at 90% for the phase δ_{CP} spans the range (-3.13, -0.39) for normal mass ordering. The CP conservation hypothesis (δ_{CP}=0, π) is excluded at 90% C.L.
Collapse
|
32
|
Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. Abstract P4-22-21: NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p4-22-21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Poly(ADP-ribose) polymerase (PARP) enzymes are involved in DNA repair and activated by DNA strand breaks. DNA damage from carboplatin is associated with activation of PARP. Preclinical data indicate that PARP inhibition potentiates the anti-tumor effect of platinum chemotherapy. Talazoparib (T) is an oral, selective PARP inhibitor with a single agent maximum tolerated dose (MTD) of 1mg orally qd. Primary dose-limiting toxicity (DLT) was thrombocytopenia. This phase I study combines T with the commonly used chemotherapy regimen of carboplatin (C) and paclitaxel (P).
Methods: Two dosing schedules are being investigated. In both schedules, C is administered on day 1 and P on days 1, 8, and 15 of a 21-day cycle. T (100-1000mcg) is dosed once daily for days 1-7 (schedule A) or days 1-3 (schedule B) starting on day 1. A 3+3 design is used for dose escalation. Key eligibility criteria include age 318 with a measurable or evaluable solid incurable malignancy. Patients (pts) must have tumor type that is expected to respond to C + P or have BRCA germline or somatic mutation. Stable, treated brain metastases are allowed. No prior C for metastatic disease is allowed. Pts must have platelets>150 and no need for anticoagulation. After 4-6 cycles of combination therapy, pts may continue the combination, change to C and intermittent T without P or change to T alone with continuous daily dosing. Each schedule will have a 6 subject dose expansion at the MTD. The starting dose level for schedule B will be the MTD from schedule A.
Results: Schedule A cohort results are reported: 11 pts (median age 59 [range 39-68]; 8 female; 3 male) have been enrolled. Pts had breast (6), ovarian (2), pancreatic (1), and SCC of oropharynx (1) and concurrent ovarian and pancreatic (1). Five pts are BRCA2+ and 3 pts are BRCA1+. Dose level 3 on schedule A (T 350mcg with C AUC 6 and P 80mg/m2) exceeded the MTD with 2 of 3 pts experiencing hematologic dose limiting toxicities (DLTs) including 1 pt with grade (gr) 3 neutropenic fever and gr 4 thrombocytopenia and another pt with grade 3/4 neutropenia lasting > 7 days. Most common AEs include neutropenia (grade 3-4: 7), anemia (grade 3-4: 3), and thrombocytopenia (grade 3-4: 4). Results from expansion of dose level 2 (T 250mcg with C AUC 6 and T 80mg/m2) will be presented. The 11 pts were on study a median of 9 weeks (range 9-36+). Four pts have discontinued study therapy: 1 due to need for anticoagulation for PE, 1 for prolonged cytopenias, and 2 for disease progression. Of the 8 pts with measurable disease evaluated for response to date, 4 had SD, 1 had a cPR, 1 had radiographic CR, and 2 with PD. A pt with BRCA 1+ triple negative breast cancer has maintained a prolonged PR (36+ weeks) even after dose reductions to T 100mcg with C AUC 3. One pt with ovarian cancer (BRCA WT) has radiographic CR (CA 125 remains mildly elevated) after 15+ weeks of therapy.
Conclusion: PARP inhibition with talazoparib days 1-7 in combination with carboplatin and paclitaxel leads to DLT of myelosuppression. However, clinical responses are seen even with lower dose combinations.
Citation Format: Turk A, Chan N, Leal T, O'Regan R, Tevaarwerk A, Rice L, Campbell T, Barroilhet L, Mehnert J, Eickhoff J, Kolesar J, Liu G, Wisinski K. NCI9782: A phase 1 study of talazoparib in combination with carboplatin and paclitaxel in patients with advanced solid tumors [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P4-22-21.
Collapse
|
33
|
Abe K, Andreopoulos C, Antonova M, Aoki S, Ariga A, Assylbekov S, Autiero D, Ban S, Barbi M, Barker GJ, Barr G, Bartet-Friburg P, Batkiewicz M, Bay F, Berardi V, Berkman S, Bhadra S, Blondel A, Bolognesi S, Bordoni S, Boyd SB, Brailsford D, Bravar A, Bronner C, Buizza Avanzini M, Calland RG, Campbell T, Cao S, Caravaca Rodríguez J, Cartwright SL, Castillo R, Catanesi MG, Cervera A, Cherdack D, Chikuma N, Christodoulou G, Clifton A, Coleman J, Collazuol G, Coplowe D, Cremonesi L, Dabrowska A, De Rosa G, Dealtry T, Denner PF, Dennis SR, Densham C, Dewhurst D, Di Lodovico F, Di Luise S, Dolan S, Drapier O, Duffy KE, Dumarchez J, Dytman S, Dziewiecki M, Emery-Schrenk S, Ereditato A, Feusels T, Finch AJ, Fiorentini GA, Friend M, Fujii Y, Fukuda D, Fukuda Y, Furmanski AP, Galymov V, Garcia A, Giffin SG, Giganti C, Gizzarelli F, Gonin M, Grant N, Hadley DR, Haegel L, Haigh MD, Hamilton P, Hansen D, Harada J, Hara T, Hartz M, Hasegawa T, Hastings NC, Hayashino T, Hayato Y, Helmer RL, Hierholzer M, Hillairet A, Himmel A, Hiraki T, Hirota S, Hogan M, Holeczek J, Horikawa S, Hosomi F, Huang K, Ichikawa AK, Ieki K, Ikeda M, Imber J, Insler J, Intonti RA, Irvine TJ, Ishida T, Ishii T, Iwai E, Iwamoto K, Izmaylov A, Jacob A, Jamieson B, Jiang M, Johnson S, Jo JH, Jonsson P, Jung CK, Kabirnezhad M, Kaboth AC, Kajita T, Kakuno H, Kameda J, Karlen D, Karpikov I, Katori T, Kearns E, Khabibullin M, Khotjantsev A, Kielczewska D, Kikawa T, Kim H, Kim J, King S, Kisiel J, Knight A, Knox A, Kobayashi T, Koch L, Koga T, Konaka A, Kondo K, Kopylov A, Kormos LL, Korzenev A, Koshio Y, Kropp W, Kudenko Y, Kurjata R, Kutter T, Lagoda J, Lamont I, Larkin E, Lasorak P, Laveder M, Lawe M, Lazos M, Lindner T, Liptak ZJ, Litchfield RP, Li X, Longhin A, Lopez JP, Ludovici L, Lu X, Magaletti L, Mahn K, Malek M, Manly S, Marino AD, Marteau J, Martin JF, Martins P, Martynenko S, Maruyama T, Matveev V, Mavrokoridis K, Ma WY, Mazzucato E, McCarthy M, McCauley N, McFarland KS, McGrew C, Mefodiev A, Metelko C, Mezzetto M, Mijakowski P, Minamino A, Mineev O, Mine S, Missert A, Miura M, Moriyama S, Mueller TA, Murphy S, Myslik J, Nakadaira T, Nakahata M, Nakamura KG, Nakamura K, Nakamura KD, Nakayama S, Nakaya T, Nakayoshi K, Nantais C, Nielsen C, Nirkko M, Nishikawa K, Nishimura Y, Novella P, Nowak J, O'Keeffe HM, Ohta R, Okumura K, Okusawa T, Oryszczak W, Oser SM, Ovsyannikova T, Owen RA, Oyama Y, Palladino V, Palomino JL, Paolone V, Patel ND, Pavin M, Payne D, Perkin JD, Petrov Y, Pickard L, Pickering L, Pinzon Guerra ES, Pistillo C, Popov B, Posiadala-Zezula M, Poutissou JM, Poutissou R, Przewlocki P, Quilain B, Radermacher T, Radicioni E, Ratoff PN, Ravonel M, Rayner MAM, Redij A, Reinherz-Aronis E, Riccio C, Rojas P, Rondio E, Roth S, Rubbia A, Rychter A, Sacco R, Sakashita K, Sánchez F, Sato F, Scantamburlo E, Scholberg K, Schoppmann S, Schwehr J, Scott M, Seiya Y, Sekiguchi T, Sekiya H, Sgalaberna D, Shah R, Shaikhiev A, Shaker F, Shaw D, Shiozawa M, Shirahige T, Short S, Smy M, Sobczyk JT, Sobel H, Sorel M, Southwell L, Stamoulis P, Steinmann J, Stewart T, Stowell P, Suda Y, Suvorov S, Suzuki A, Suzuki K, Suzuki SY, Suzuki Y, Tacik R, Tada M, Takahashi S, Takeda A, Takeuchi Y, Tanaka HK, Tanaka HA, Terhorst D, Terri R, Thakore T, Thompson LF, Tobayama S, Toki W, Tomura T, Touramanis C, Tsukamoto T, Tzanov M, Uchida Y, Vacheret A, Vagins M, Vallari Z, Vasseur G, Wachala T, Wakamatsu K, Walter CW, Wark D, Warzycha W, Wascko MO, Weber A, Wendell R, Wilkes RJ, Wilking MJ, Wilkinson C, Wilson JR, Wilson RJ, Yamada Y, Yamamoto K, Yamamoto M, Yanagisawa C, Yano T, Yen S, Yershov N, Yokoyama M, Yoo J, Yoshida K, Yuan T, Yu M, Zalewska A, Zalipska J, Zambelli L, Zaremba K, Ziembicki M, Zimmerman ED, Zito M, Żmuda J. Measurement of Coherent π^{+} Production in Low Energy Neutrino-Carbon Scattering. PHYSICAL REVIEW LETTERS 2016; 117:192501. [PMID: 27858422 DOI: 10.1103/physrevlett.117.192501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/15/2016] [Indexed: 06/06/2023]
Abstract
We report the first measurement of the flux-averaged cross section for charged current coherent π^{+} production on carbon for neutrino energies less than 1.5 GeV, and with a restriction on the final state phase space volume in the T2K near detector, ND280. Comparisons are made with predictions from the Rein-Sehgal coherent production model and the model by Alvarez-Ruso et al., the latter representing the first implementation of an instance of the new class of microscopic coherent models in a neutrino interaction Monte Carlo event generator. We observe a clear event excess above background, disagreeing with the null results reported by K2K and SciBooNE in a similar neutrino energy region. The measured flux-averaged cross sections are below those predicted by both the Rein-Sehgal and Alvarez-Ruso et al.
Collapse
|
34
|
Campbell T, Ponder B, Meyer K. Novel regulators of ESR1 activity. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61096-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
35
|
Theurich G, DeLuca C, Campbell T, Liu F, Saint K, Vertenstein M, Chen J, Oehmke R, Doyle J, Whitcomb T, Wallcraft A, Iredell M, Black T, da Silva AM, Clune T, Ferraro R, Li P, Kelley M, Aleinov I, Balaji V, Zadeh N, Jacob R, Kirtman B, Giraldo F, McCarren D, Sandgathe S, Peckham S, Dunlap R. THE EARTH SYSTEM PREDICTION SUITE: Toward a Coordinated U.S. Modeling Capability. BULLETIN OF THE AMERICAN METEOROLOGICAL SOCIETY 2016; 97:1229-1247. [PMID: 29568125 PMCID: PMC5859946 DOI: 10.1175/bams-d-14-00164.1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
The Earth System Prediction Suite (ESPS) is a collection of flagship U.S. weather and climate models and model components that are being instrumented to conform to interoperability conventions, documented to follow metadata standards, and made available either under open source terms or to credentialed users. The ESPS represents a culmination of efforts to create a common Earth system model architecture, and the advent of increasingly coordinated model development activities in the U.S. ESPS component interfaces are based on the Earth System Modeling Framework (ESMF), community-developed software for building and coupling models, and the National Unified Operational Prediction Capability (NUOPC) Layer, a set of ESMF-based component templates and interoperability conventions. This shared infrastructure simplifies the process of model coupling by guaranteeing that components conform to a set of technical and semantic behaviors. The ESPS encourages distributed, multi-agency development of coupled modeling systems, controlled experimentation and testing, and exploration of novel model configurations, such as those motivated by research involving managed and interactive ensembles. ESPS codes include the Navy Global Environmental Model (NavGEM), HYbrid Coordinate Ocean Model (HYCOM), and Coupled Ocean Atmosphere Mesoscale Prediction System (COAMPS®); the NOAA Environmental Modeling System (NEMS) and the Modular Ocean Model (MOM); the Community Earth System Model (CESM); and the NASA ModelE climate model and GEOS-5 atmospheric general circulation model.
Collapse
|
36
|
Khambalia HA, Moinuddin Z, Summers AM, Tavakoli A, Pararajasingam R, Campbell T, Dhanda R, Forgacs B, Augustine T, van Dellen D. A prospective cohort study of risk prediction in simultaneous pancreas and kidney transplantation. Ann R Coll Surg Engl 2015; 97:445-50. [PMID: 26274754 PMCID: PMC5126239 DOI: 10.1308/rcsann.2015.0001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/19/2015] [Indexed: 01/04/2023] Open
Abstract
INTRODUCTION Current risk prediction scoring systems in pancreas transplantation are limited to organ factors and are specific to predicting graft outcome. They do not consider recipient factors or inform regarding recipient morbidity. The aim of this study was to assess the utility of commonly used general surgical risk prediction models (P-POSSUM [Portsmouth Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity], MODS [multiple organ dysfunction score], Charlson co-morbidity index, revised cardiac risk index, ASA [American Society of Anesthesiologists] grade and Waterlow score), and to correlate them with total length of hospital stay (LOS) and critical care unit (CCU) LOS, important surrogate markers of patient outcome. METHODS All risk prediction scores were calculated prospectively for all simultaneous pancreas and kidney (SPK) transplant recipients from November 2011 to October 2013, and correlated with outcome measures. RESULTS Overall, 57 SPK transplant recipients were analysed. The mean age was 42.0 years (standard deviation [SD]: 7.60 years), 27 (52%) were male and the mean body mass index was 25.43kg/m(2) (SD: 3.11kg/m(2)). The mean pancreas and kidney cold ischaemic times were 703 minutes (SD: 182 minutes) and 850 minutes (SD: 192 minutes) respectively. The median total LOS and mean CCU LOS was 17 days (range: 8-79 days) and 7 days (SD: 4.04 days) respectively. When correlated with risk prediction scores, Waterlow score was the only significant predictor of total LOS and CCU LOS (p<0.001 [Spearman's correlation] and p=0.001 [Pearson's correlation] respectively). CONCLUSIONS Preoperative risk prediction plays an important part in planning perioperative care. To date, no validated risk prediction scoring system exists for SPK transplantation. This prospective study indicates that Waterlow score identifies high risk individuals and has value in the prediction of outcome following SPK transplantation.
Collapse
|
37
|
Campbell T, Pengo MF, Steier J. Patients' preference of established and emerging treatment options for obstructive sleep apnoea. J Thorac Dis 2015; 7:938-42. [PMID: 26101652 DOI: 10.3978/j.issn.2072-1439.2015.04.53] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2014] [Accepted: 01/08/2015] [Indexed: 11/14/2022]
Abstract
BACKGROUND Obstructive sleep apnoea (OSA) is the most common form of sleep-disordered breathing. The standard treatment, continuous positive airway pressure (CPAP), has limited long-term compliance. Alternative treatment options are required and new methods, including hypoglossal nerve stimulation (HNS) and continuous transcutaneous electrical stimulation (CTES), are currently emerging. We report on patients' preference for different treatments of OSA. METHODS We recorded patients' age, gender, body mass index (BMI), Epworth Sleepiness Scale (ESS), Functional Outcomes of Sleep Questionnaire with 10 questions (FOSQ10), severity of OSA, and current treatment. We showed pictures of existing [CPAP, mandibular advancement device (MAD)] and emerging treatments (HNS and CTES). We then asked (I) whether participants were interested in further information about HNS/CTES; (II) if they would be willing to try HNS/CTES; and (III) if they were to choose only one of the four listed treatments, which one would they prefer to use every night. RESULTS One hundred sixty-two patients completed the survey {81 males, mean age 52 [12] years, BMI 34 [7] kg/m(2), ESS 10.2 (6.0) points, FOSQ10 28.5 (8.1) points}. The majority of the respondents (89.5%) had been diagnosed with OSA. A total of 91.3% of the respondents were interested in more information and were willing to try HNS/CTES. Most respondents preferred the potential use of CTES (56.7%), while 21.7% chose HNS, 17.8% CPAP, and 3.8% the MAD. There were no differences in the characteristics of the patients who preferred CTES compared to those who preferred other treatments, but a regression analysis revealed that a low ESS score was an independent predictor of patients choosing CTES (P<0.05). CONCLUSIONS More than 9 out of 10 of the respondents were interested in trying emerging technologies to treat OSA, most preferring CTES. Less sleepy patients were more likely to choose less invasive treatments. These findings will likely impact on future research and development of therapies for sleep-disordered breathing.
Collapse
|
38
|
Harkins KM, Buikstra JE, Campbell T, Bos KI, Johnson ED, Krause J, Stone AC. Screening ancient tuberculosis with qPCR: challenges and opportunities. Philos Trans R Soc Lond B Biol Sci 2015; 370:20130622. [PMID: 25487341 PMCID: PMC4275897 DOI: 10.1098/rstb.2013.0622] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
The field of ancient DNA (aDNA) has rapidly accelerated in recent years as a result of new methods in next-generation sequencing, library preparation and targeted enrichment. Such research is restricted, however, by the highly variable DNA preservation within different tissues, especially when isolating ancient pathogens from human remains. Identifying positive candidate samples via quantitative PCR (qPCR) for downstream procedures can reduce reagent costs, increase capture efficiency and maximize the number of sequencing reads of the target. This study uses four qPCR assays designed to target regions within the Mycobacterium tuberculosis complex (MTBC) to examine 133 human skeletal samples from a wide geographical and temporal range, identified by the presence of skeletal lesions typical of chronic disseminated tuberculosis. Given the inherent challenges working with ancient mycobacteria, strict criteria must be used and primer/probe design continually re-evaluated as new data from bacteria become available. Seven samples tested positive for multiple MTBC loci, supporting them as strong candidates for downstream analyses. Using strict and conservative criteria, qPCR remains a fast and effective screening tool when compared with screening by more expensive sequencing and enrichment technologies.
Collapse
|
39
|
Campbell T, Pengo M, Brown R, Birdseye A, Bacon K, Steier J. P295 Patients' Preference Of Established And Emerging Treatments For Obstructive Sleep Apnoea. Thorax 2014. [DOI: 10.1136/thoraxjnl-2014-206260.413] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
Campbell T, Tindall DJ, Figg WD. Dihydrotestosterone synthesis from adrenal precursors does not involve testosterone in castration-resistant prostate cancer. Cancer Biol Ther 2014; 13:237-8. [DOI: 10.4161/cbt.19608] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
41
|
Hensman Moss D, Poulter M, Beck J, Polke J, Campbell T, Adamson G, Hehir J, Mudanohwo E, McColgan P, Wild E, Haworth A, Sweeney M, Houlden H, Mead S, Tabrizi S. K11 C9orf72 Expansions Are The Most Common Genetic Cause Of Huntington's Disease Phenocopy Presentations In A Uk Cohort. J Neurol Psychiatry 2014. [DOI: 10.1136/jnnp-2014-309032.235] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
42
|
Slattery C, Beck J, Harper L, Adamson G, Abdi Z, Uphill J, Campbell T, Druyeh R, Mahoney C, Rohrer J, Kenny J, Lowe J, Leung K, Barnes J, Clegg S, Blair M, Nicholas J, Guerreiro R, Rowe J, Ponto C, Zerr I, Kretzschmar H, Gambetti P, Crutch S, Warren J, Rossor M, Fox N, Collinge J, Schott J, Mead S. TREM2 VARIANTS INCREASE RISK OF TYPICAL EARLY-ONSET ALZHEIMER'S DISEASE BUT NOT OF PRION OR FRONTOTEMPORAL DEMENTIA. Journal of Neurology, Neurosurgery and Psychiatry 2014. [DOI: 10.1136/jnnp-2014-308883.7] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
43
|
Stenz J, Schwartz S, Croteau D, Campbell T. Impact of transitioning to antibiotic-impregnated PICCs on blood stream infection rate at a large tertiary institution. J Vasc Interv Radiol 2013. [DOI: 10.1016/j.jvir.2013.01.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
44
|
Di Benedetto G, van Dellen D, Ghazanfar A, Tavakoli A, Delargy M, Griffin C, Forgacs B, Campbell T, Parrott NR, Pararajasingam R, Wood G, Woywodt A, Picton M, Augustine T. Does Rapamycin Still Have a Role? Experience and Lessons from the Last Decade. Transplantation 2012. [DOI: 10.1097/00007890-201211271-01475] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
45
|
Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile. Sci Transl Med 2012; 4:128ra39. [DOI: 10.1126/scitranslmed.3003651] [Citation(s) in RCA: 872] [Impact Index Per Article: 72.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
46
|
Tate DF, Sampat M, Harezlak J, Fiecas M, Hogan J, Dewey J, McCaffrey D, Branson D, Russell T, Conley J, Taylor M, Schifitto G, Zhong J, Daar ES, Alger J, Brown M, Singer E, Campbell T, McMahon D, Tso Y, Matesan J, Letendre S, Paulose S, Gaugh M, Tripoli C, Yiannoutsos C, Bigler ED, Cohen RA, Guttmann CRG, Navia B. Erratum to: Regional areas and widths of the midsagittal corpus callosum among HIV-infected patients on stable antiretroviral therapies. J Neurovirol 2011. [DOI: 10.1007/s13365-011-0051-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
47
|
Daniel SE, Aref A, Rabbani C, Taylor R, Campbell T, Shamsa F, Chuba PJ. Three-dimensional visualization of stranded source migration following prostate brachytherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.79] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
79 Background: The use of radioactive seeds embedded in absorbable vicryl suture material has emerged as one preferred method for prostate cancer brachytherapy. However, it is unclear how strand displacement affects post-implant dosimetry. Our objective was to use CT imaging and 3D reconstruction to determine strand displacement between day zero and day 30 and to assess the dosimetric consequences of strand displacement. Methods: Between March 2006 and December 2009 there were 86 prostate brachytherapy patients with day zero and day 30 post-plan imaging. There was a mean of 18.24 strands per implant, 9.81 loose seeds per implant, and 69.08 total seeds per implant. Substantial strand displacement was identified by inspection. Migrated strands were identified on day zero and day 30 scans and the distance of displacement was measured using 3D fusion software. Results: Of 1550 strands placed, 23 were found to show substantial migration revealed by 3D imaging. These displacements occurred in 21 of the 86 cases. The estimated distance of strand displacement ranged from 0.5 cm to 2.5 cm with an average movement of 1.5 cm. The exact distance of strand displacement ranged from 0.31 m to 3.44 cm, with mean movement of 2.75 cm. Conclusions: 3D imaging reveals unexpected spatial instability in stranded brachytherapy sources. Significant movement may be expected to occur in approximately 1.48% of stranded sources and 24.42% of cases. Factors which predict for the migration of sources remain relatively undefined. Minimal dosimetric effects from strand displacement appear to be offset by resolution of prostate edema. [Table: see text] No significant financial relationships to disclose.
Collapse
|
48
|
Campbell T, Allard R, Preller R, Smedstad L, Wallcraft A, Sue Chen, Hao Jin, Gaberšek S, Hodur R, Reich J, Fry CD, Eccles V, Hwai-Ping Cheng, Cheng JRC, Hunter R, DeLuca C, Theurich G. Integrated Modeling of the Battlespace Environment. Comput Sci Eng 2010. [DOI: 10.1109/mcse.2010.78] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
49
|
Wan Q, Harris M, Zwar N, Vagholkar S, Kemp L, Campbell T. Experience in implementation of cardiovascular absolute risk assessment and management in Australian general practice. Int J Clin Pract 2010; 64:1166-7. [PMID: 20642716 DOI: 10.1111/j.1742-1241.2010.02403.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
50
|
Ghazanfar A, Tavakoli A, Zaki MR, Pararajasingam R, Campbell T, Parrott NR, Augustine T, Riad HN. The Outcomes of Living Donor Renal Transplants With Multiple Renal Arteries: A Large Cohort Study With a Mean Follow-Up Period of 10 Years. Transplant Proc 2010; 42:1654-8. [PMID: 20620494 DOI: 10.1016/j.transproceed.2009.12.067] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2009] [Accepted: 12/08/2009] [Indexed: 02/05/2023]
|